TipRanks
Haemonetics Corp. (HAE)
NYSE:HAE
US Market
Want to see HAE full AI Analyst Report?

Haemonetics (HAE) Stock Forecast & Price Target

447 Followers
See the Price Targets and Ratings of:

HAE Analyst Ratings

Strong Buy
9Ratings
Strong Buy
7 Buy
2 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Haemonetics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HAE Stock 12 Month Forecast

Average Price Target

$125.38
▲(19.40% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $125.38 with a high forecast of $140.00 and a low forecast of $86.00. The average price target represents a 19.40% change from the last price of $105.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","94":"$94","141":"$141","70.5":"$70.5","117.5":"$117.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125.375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$125.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$86.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,70.5,94,117.5,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.37,107.11076923076924,109.85153846153847,112.5923076923077,115.33307692307693,118.07384615384616,120.8146153846154,123.55538461538461,126.29615384615386,129.03692307692307,131.77769230769232,134.51846153846154,137.25923076923078,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.37,105.98576923076924,107.60153846153847,109.2173076923077,110.83307692307693,112.44884615384616,114.0646153846154,115.68038461538461,117.29615384615384,118.91192307692307,120.5276923076923,122.14346153846154,123.75923076923077,{"y":125.375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.37,102.95692307692308,101.54384615384616,100.13076923076923,98.71769230769232,97.30461538461539,95.89153846153846,94.47846153846154,93.06538461538462,91.65230769230769,90.23923076923077,88.82615384615384,87.41307692307693,{"y":86,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.88,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.54,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.95,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.37,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$140.00Average Price Target$125.38Lowest Price Target$86.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on HAE
Mizuho Securities
Mizuho Securities
$95→$140
Buy
33.33%
Upside
Reiterated
10/09/26
Haemonetics price target raised to $140 from $95 at MizuhoHaemonetics price target raised to $140 from $95 at Mizuho
Barrington Analyst forecast on HAE
Barrington
Barrington
$118→$140
Buy
33.33%
Upside
Reiterated
10/09/26
Haemonetics price target raised to $140 from $118 at BarringtonHaemonetics price target raised to $140 from $118 at Barrington
Bank of America Securities Analyst forecast on HAE
Bank of America Securities
Bank of America Securities
$120→$140
Buy
33.33%
Upside
Reiterated
10/08/26
Analysts Are Bullish on These Healthcare Stocks: Alignment Healthcare (ALHC), Humana (HUM)
BTIG
$110→$130
Buy
23.81%
Upside
Reiterated
10/08/26
Haemonetics price target raised to $130 from $110 at BTIGHaemonetics price target raised to $130 from $110 at BTIG
Citi
$92→$123
Buy
17.14%
Upside
Upgraded
09/18/26
Haemonetics upgraded to Buy from Neutral at CitiHaemonetics upgraded to Buy from Neutral at Citi
Raymond James Analyst forecast on HAE
Raymond James
Raymond James
$105→$125
Buy
19.05%
Upside
Reiterated
09/03/26
Haemonetics price target raised to $125 from $105 at Raymond JamesHaemonetics price target raised to $125 from $105 at Raymond James
Robert W. Baird Analyst forecast on HAE
Robert W. Baird
Robert W. Baird
$96→$119
Buy
13.33%
Upside
Reiterated
08/21/26
Haemonetics price target raised to $119 from $96 at BairdHaemonetics price target raised to $119 from $96 at Baird
Needham
―
Hold
―
Reiterated
08/18/26
Haemonetics: CSL Plasma Migration Deal Highlights Long-Term Upside but Near-Term Risk/Reward Keeps Rating at Hold
J.P. Morgan Analyst forecast on HAE
J.P. Morgan
J.P. Morgan
$86
Hold
-18.10%
Downside
Reiterated
08/10/26
J.P. Morgan Sticks to Its Hold Rating for Haemonetics (HAE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on HAE
Mizuho Securities
Mizuho Securities
$95→$140
Buy
33.33%
Upside
Reiterated
10/09/26
Haemonetics price target raised to $140 from $95 at MizuhoHaemonetics price target raised to $140 from $95 at Mizuho
Barrington Analyst forecast on HAE
Barrington
Barrington
$118→$140
Buy
33.33%
Upside
Reiterated
10/09/26
Haemonetics price target raised to $140 from $118 at BarringtonHaemonetics price target raised to $140 from $118 at Barrington
Bank of America Securities Analyst forecast on HAE
Bank of America Securities
Bank of America Securities
$120→$140
Buy
33.33%
Upside
Reiterated
10/08/26
Analysts Are Bullish on These Healthcare Stocks: Alignment Healthcare (ALHC), Humana (HUM)
BTIG
$110→$130
Buy
23.81%
Upside
Reiterated
10/08/26
Haemonetics price target raised to $130 from $110 at BTIGHaemonetics price target raised to $130 from $110 at BTIG
Citi
$92→$123
Buy
17.14%
Upside
Upgraded
09/18/26
Haemonetics upgraded to Buy from Neutral at CitiHaemonetics upgraded to Buy from Neutral at Citi
Raymond James Analyst forecast on HAE
Raymond James
Raymond James
$105→$125
Buy
19.05%
Upside
Reiterated
09/03/26
Haemonetics price target raised to $125 from $105 at Raymond JamesHaemonetics price target raised to $125 from $105 at Raymond James
Robert W. Baird Analyst forecast on HAE
Robert W. Baird
Robert W. Baird
$96→$119
Buy
13.33%
Upside
Reiterated
08/21/26
Haemonetics price target raised to $119 from $96 at BairdHaemonetics price target raised to $119 from $96 at Baird
Needham
―
Hold
―
Reiterated
08/18/26
Haemonetics: CSL Plasma Migration Deal Highlights Long-Term Upside but Near-Term Risk/Reward Keeps Rating at Hold
J.P. Morgan Analyst forecast on HAE
J.P. Morgan
J.P. Morgan
$86
Hold
-18.10%
Downside
Reiterated
08/10/26
J.P. Morgan Sticks to Its Hold Rating for Haemonetics (HAE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
KNSAKiniksa Pharmaceuticals
OMCLOmnicell
AXGNAxoGen
ONCBeOne Medicines
AHCOAdaptHealth
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Haemonetics

3 Months
Anthony PetroneMizuho Securities
Success Rate
22/42 ratings generated profit
52%
Average Return
+2.45%
Copying Anthony Petrone's trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of +2.45% per trade.
1 Year
Anthony PetroneMizuho Securities
Success Rate
25/42 ratings generated profit
60%
Average Return
+12.80%
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 59.52% of your transactions generating a profit, with an average return of +12.80% per trade.
2 Years
Michael PetuskyBarrington
Success Rate
28/45 ratings generated profit
62%
Average Return
+24.85%
Copying Michael Petusky's trades and holding each position for 2 Years would result in 62.22% of your transactions generating a profit, with an average return of +24.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HAE Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
1
1
0
0
0
Buy
8
9
15
13
15
Hold
4
4
6
6
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
14
21
19
20
In the current month, HAE has received 15 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. HAE average Analyst price target in the past 3 months is 125.38.
Each month's total comprises the sum of three months' worth of ratings.

HAE Financial Forecast

HAE Earnings Forecast

Next quarter’s earnings estimate for HAE is $1.29 with a range of $1.21 to $1.37. The previous quarter’s EPS was $1.14. HAE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HAE has Performed in-line its overall industry.
Next quarter’s earnings estimate for HAE is $1.29 with a range of $1.21 to $1.37. The previous quarter’s EPS was $1.14. HAE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HAE has Performed in-line its overall industry.

HAE Sales Forecast

Next quarter’s sales forecast for HAE is $345.15M with a range of $338.04M to $354.73M. The previous quarter’s sales results were $339.38M. HAE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HAE has Performed in-line its overall industry.
Next quarter’s sales forecast for HAE is $345.15M with a range of $338.04M to $354.73M. The previous quarter’s sales results were $339.38M. HAE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HAE has Performed in-line its overall industry.

HAE Stock Forecast FAQ

What is HAE’s average 12-month price target, according to analysts?
Based on analyst ratings, Haemonetics Corp.’s 12-month average price target is 125.38.
    What is HAE’s upside potential, based on the analysts’ average price target?
    Haemonetics Corp. has 19.40% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HAE a Buy, Sell or Hold?
          Haemonetics Corp. has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Haemonetics Corp.’s price target?
            The average price target for Haemonetics Corp. is 125.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $140.00 ,the lowest forecast is $86.00. The average price target represents 19.40% Increase from the current price of $105.
              What do analysts say about Haemonetics Corp.?
              Haemonetics Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of HAE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.